



Republic of the Philippines
Department of Health

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2018-264-A

03 October 2018

RECOMMENDING APPROVAL OF THE AWARD OF CONTRACT FOR THE PROCUREMENT OF FILGRASTIM 300MCG INJECTION – RE-BID IB NO. 2018-077-A

WHEREAS, Open Competitive Bidding for the Procurement of Filgrastim 300mcg Injection – Re-Bid was conducted in accordance with Republic Act (RA) 9184 and its 2016 Revised Implementing Rules and Regulations (IRR) through the General Appropriations Act of 2018 with a Total Approved Budget for the Contract of Fourteen Million Four Hundred Fifty Seven Thousand Eighty Philippine Pesos (PhP14,457,080.00):

Item No.	Particular	Quantity	Unit	Total ABC (PhP)
1	Filgrastim 300mcg Injection	8,800	Pre-filled syringe	14,457,080.00

WHEREAS, the COBAC Resolution No. 2018-264, “Declaration of Failure of Bidding for the Procurement of Filgrastim 300mcg Injection under IB No. 2018-077” was approved;

WHEREAS, Purchase Request (PR) was received from Disease Prevention Control Bureau (DPCB) – Non Communicable Diseases Prevention and Control Program (NCDPCP);

WHEREAS, 30 May 2018, Pre-procurement Conference was conducted at 10:00 AM at Central Office Bids and Awards Committee (COBAC) Conference Room, Department of Health (DOH), to discuss the details of the procurement at hand;

WHEREAS, on 04 June 2018, a memorandum was issued to DPCB - NCDPCP on the issues and concerns raised during the above cited conference;

WHEREAS, on 05 June 2018, DPCB- NCDPCP submitted the revised PR;

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2018-299 dated 08 June 2018;

WHEREAS, on 11 June 2018, the IB was published in one (1) newspaper of general nationwide circulation, the Philippine Manila Standard Publishing, Inc. and was posted in the PhilGEPS website and in conspicuous places within the premises of the DOH;

WHEREAS, on 19 June 2018, a Pre-bidding Conference took place as scheduled at 10:00 AM at the COBAC Conference Room, DOH, with one (1) prospective bidder participating, namely, Zuellig Pharma Corp. (ZPC);

WHEREAS, during the said Pre-bidding Conference, clarifications on the eligibility requirements and technical specifications were discussed;

WHEREAS, on 03 July 2018, the Submission and Opening of Bids took place as scheduled at 9:00 A.M. at the COBAC Conference Room, DOH, with two (2) prospective bidders submitted their bid, namely:

1. ZPC JV with Interphil Laboratories Inc. (ILI); and,
2. Phil Pharmawalth Inc. (PPI).

WHEREAS, the first envelopes, containing the Eligibility and Technical Document were individually opened and the presence, completeness and correctness of all the documents were verified by the COBAC-A in the presence of the prospective bidders’ representatives. Upon examination, ZPC JV with ILI and PPI were declared “ELIGIBLE.”

WHEREAS, the second envelopes, containing the Financial Proposal were individually opened and the presence, completeness and correctness of the Financial Documents were verified by the COBAC-A in the presence of the bidders' representatives. Upon examination, the two (2) "ELIGIBLE" bidders were rated "PASSED" and subsequently their respective bids were read out publicly and posted in the Abstract of Bids to wit:

Name of Company				ZPC JV with ILI	PPI
Bid Security				BID SECURING DECLARATION	BID SECURING DECLARATION
Amount				N/A	N/A
Validity				N/A	N/A
REMARKS				ELIGIBLE / PASSED	ELIGIBLE / PASSED
Item No.	Item Description	Qty.	Unit	TOTAL ABC (Php)	BID PRICE AS READ (Php)
1	Filgrastim 300mcg Injection	8,800	Pre-filled syringe	14,457,080.00	13,094,400.00
					6,355,624.00

WHEREAS, PPI was declared as the Lowest Bidder (LB) subject to further arithmetical review and corrections of the financial bid to determine the bonafide Lowest Calculated Bid (LCB);

WHEREAS, the bids for the item listed below were found to be substantially complying:

8,800 pre-filled syringe of Filgrastim 300mcg Injection

Bidder No.	Name of Company	ABC (Php)	Bid as Calculated Amount (Php)	% Variance from ABC
2	PPI	14,457,080.00	6,355,624.00	56.03%
1	ZPC JV with ILI		13,094,400.00	9.42%

WHEREAS, on 04 July 2018, the Bid Evaluation of the submitted proposal of PPI on the legal, technical and financial aspects was undertaken by the designated TWG;

WHEREAS, on 12 July 2018, the TWG found PPI "non-compliant" on the technical requirement and submitted its report;

WHEREAS, on 17 July 2018, the TWG report on the bid of PPI was presented to COBAC-A during its 27th Regular Meeting. Upon deliberation, the Committee concurred with the TWG to declared PPI "non-compliant" and proceeded with the evaluation of the next LCB;

WHEREAS, on 20 July 2018, the COBAC-A issued a notification to PPI informing its non-compliance with the technical requirement;

WHEREAS, on the same date, the TWG submitted its report on the bid of the second (2nd) LB, ZPC JV with ILI was found "compliant" with the legal and financial requirement and requested for clarification on the technical requirement, particularly on the submitted Certificate of Exclusive Distributorship (CED);

WHEREAS, PPI did not file its Request for Reconsideration (RFR) three (3) calendar days upon issuance of the notice of non-compliance;

WHEREAS, on 02 August 2018, the TWG report on the bid of ZPC JV with ILI was presented to COBAC-A during its 29th Regular Meeting. Upon deliberation, the Committee concurred with the TWG to clarify the technical findings;

WHEREAS, on the same date, the COBAC-A issued a clarification letter to ZPC JV with ILI on the technical finding;

WHEREAS, on 03 and 06 of August 2018, ZPC JV with ILI submitted its response and was subsequently forwarded to the designated Technical-TWG, for further evaluation;

WHEREAS, on 13 August 2018, the Technical-TWG found ZPC JV with ILI "compliant" with the requirement based on the submitted response;

WHEREAS, on 14 August 2018, the TWG report was presented to COBAC-A, upon deliberation, the Committee concurred with the TWG and decided to proceed with the post-qualification evaluation upon receipt of the documentary requirements;

WHEREAS, on the same date, a notification was issued to ZPC JV with ILI requesting for the submission of post-qualification requirements;

WHEREAS, on 20 August 2018, ZPC JV with ILI submitted its post-qualification documents which were considered within the prescribed timelines taking into consideration that the last day in the period of prescription falls on a Sunday which is a non-working day. Further, the said documents were subsequently forwarded to the designated TWG, for evaluation;

WHEREAS, on 28 August 2018, the TWG found ZPC JV with ILI "responsive" on its legal and technical post-qualification documents and requested clarification on its financial documents;

WHEREAS, on the same date, the TWG report on the Post-qualification documents was presented to COBAC -A during its 33rd Regular Meeting. Upon review and deliberation, the Committee concurred with the TWG report to clarify the said finding;

WHEREAS, on the same date, COBAC-A issued a request for clarification through electronic mail (e-mail) and facsimile to ZPC JV with ILI;

WHEREAS, on 03 and 10 of September 2018, ZPC JV with ILI submitted its response and were subsequently forwarded to the designated TWG, for further evaluation;

WHEREAS, on 24 September 2018, the TWG found ZPC JV with ILI "responsive" as to submitted responses;

WHEREAS, on 02 October 2018, the final TWG report on the Post-qualification documents was presented to COBAC -A during its 37th Regular Meeting. Upon review and deliberation, the Committee concurred with the TWG report and declared ZPC JV with ILI "post-qualified" for the said item and recommended the award of contract;

WHEREAS, on 03 October 2018, the TWG submitted the Bid Evaluation and Post Qualification Evaluation Reports citing ZPC JV with ILI "responsive" on the submitted documents;

WHEREAS, the COBAC-A reviewed and deliberated the TWG reports, as well as the documents and responses submitted by ZPC JV with ILI. The following are the salient points of discussion:

Item No.	Description	Name of Bidder	Bidder's Rank	ABC Price (Php)	Bid Price (Php)	TWG		COBAC	
						Finding	Recommendation	Finding	Recommendation
1	8,800 pre-filled syringe of Filgrastim 300mcg Injection	ZPC JV with ILI	2 nd LCB	14,457,080.00	13,094,400.00	The 2 nd LCB passed the post qualification and found to have complied with the legal, technical and financial requirements and submitted response	Responsive	<ul style="list-style-type: none"> COBAC confirms with the recommendation of the TWG. ZPC JV with ILI is determined to be responsive and post-qualified and recommended for the award of contract 	Lowest Calculated and Responsive Bid (LCRB)

WHEREAS, at the time of the signing of this resolution, there is no pending incident, no pending Motion for Reconsideration, no pending Protest and the COBAC-A followed the requirements set forth in R.A. 9184;

NOW THEREFORE, on the basis of the above, the herein members of the COBAC-A **HEREBY RESOLVE** to recommend the award of contract to **Zuellig Pharma Corp. JV** with **Interphil Laboratories Inc.** determined as the LCRB with a Total Contract Price of **Thirteen Million Ninety Four Thousand Four Hundred Philippine Pesos (Php13,094,400.00)** inclusive of other taxes for the items listed below:

Item No.	Particular	Qty.	Unit	Total Bid Price (Php)
1	Filgrastim 300mcg Injection	8,800	Pre-filled syringe	13,094,400.00

Signed this OCT 05 2018 day of 2018 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) - A


LEONITA P. GORGOLON, MHA, MCHM, CEO VI
Regular Member


FERCHITO L. AVELLINO, MD, PHSAE
Regular Member


KENNETH G. RONQUILLO, MD, MPH, CESO III
Vice-Chairperson


MAR WYNN C. BELLO, MD, MPA
Regular Member

NESTOR F. SANTIAGO, JR., MD, MPH, MHS, CESO III
Assistant Secretary of Health
Chairperson

By Authority of the Secretary of Health:


MYRNA C. CABOTAJE, MD, MPH, CESO III
OIC, Undersecretary of Health
Public Health Service Team

OCT 22 2018